Zobrazeno 1 - 3
of 3
pro vyhledávání: '"A2A, adenosine 2A"'
Autor:
Lu Feng, Kai Zhang, Bo Liu, Tingting Jiang, Liang Ouyang, Guan Wang, Jiamei Li, Shiou Zhu, Junping Pei
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 10, Pp 3015-3034 (2021)
Acta Pharmaceutica Sinica. B
Acta Pharmaceutica Sinica. B
Parkinson's disease (PD), known as one of the most universal neurodegenerative diseases, is a serious threat to the health of the elderly. The current treatment has been demonstrated to relieve symptoms, and the discovery of new small-molecule compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d12dab43aca56bfd6a912c2aa71297ff
http://www.sciencedirect.com/science/article/pii/S2211383521000642
http://www.sciencedirect.com/science/article/pii/S2211383521000642
Autor:
Marie D. Ralff, Benedito A. Carneiro, Lanlan Zhou, Wen-I Chang, Rohinton Tarapore, Varun V. Prabhu, Joshua N. Honeyman, Attila A. Seyhan, Isacco Ferrarini, Alexander G. Raufi, Lindsey Carlsen, Martin Stogniew, Lee Schalop, Robyn Borsuk, Joshua E. Allen, Aakash Jhaveri, Cassandra Parker, Sara Morrow, Young Lee, Fabio Tavora, Wolfgang Oster, Jocelyn E. Ray, Kelsey E. Huntington, Howard Safran, Anna D Louie, Abed Rahman Kawakibi, Yiqun Zhang, Wafik S. El-Deiry
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
Neoplasia: An International Journal for Oncology Research, Vol 22, Iss 12, Pp 725-744 (2020)
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G protein coupled receptor (GPCR) dopamine receptor D2 (DRD2), and as an allosteric agon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788cb5d6703ffa407652b681a16c6c03
http://europepmc.org/articles/PMC7588802
http://europepmc.org/articles/PMC7588802
Autor:
Zhang K; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Zhu S; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Li J; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Jiang T; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Feng L; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Pei J; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Wang G; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.; Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, China., Ouyang L; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China., Liu B; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
Publikováno v:
Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2021 Oct; Vol. 11 (10), pp. 3015-3034. Date of Electronic Publication: 2021 Feb 26.